Genmab — Juli 2019
-
"Barclays skruer en tand op for kursmålet for en aktie i Genmab. Det er nu sat til 1400 kr. fra 1300 kr.
Anbefalingen "overvægt" fastholdes, fremgår det data fra Bloomberg News.
Dermed er der lidt over 14 pt. op til det aktuelle kursmål på 1227 kr. efter en stigning torsdag på 0,9 pct.
Ifølge Bloomberg er analytikernes gennemsnitlige kursmål på 1317,57 kr."
/ritzau/FINANS
-
FDA has granets accelerated approval to Selinexor. https://newatlas.com/selinexor-new-cancer-drug-fda/60659/
-
Spændende om vi får samme situation som i går inden luk. Da gik den fuldstændig i selvsving.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
